Literature DB >> 33509508

Potential mechanisms underlying the ameliorative effect of Lactobacillus paracasei FZU103 on the lipid metabolism in hyperlipidemic mice fed a high-fat diet.

Xu-Cong Lv1, Min Chen2, Zi-Rui Huang2, Wei-Ling Guo3, Lian-Zhong Ai4, Wei-Dong Bai5, Xiao-Dan Yu2, Ying-Li Liu6, Ping-Fan Rao7, Li Ni7.   

Abstract

Lactobacillus paracasei FZU103, a probiotic previously isolated from the traditional brewing process of Hongqu rice wine, may have the beneficial effect of improving the disorder of lipid metabolism. This study aimed to determine the beneficial effects of L. paracasei FZU103 on improving hepatic lipid accumulation associated with hyperlipidemia. Results indicated that L. paracasei FZU103 intervention significantly inhibited the abnormal growth of body weight and epididymal white adipose tissue (eWAT), prevented the hypertrophy of epididymal adipocytes, ameliorated the biochemical parameters of serum and liver related to lipid metabolism in HFD-fed mice. Histological analysis also showed that the excessive accumulation oflipid dropletsin the livers induced by HFD-feeding was greatly alleviated by L. paracasei FZU103 intervention. In addition, L. paracasei FZU103 also promoted the excretion of bile acids (BAs) through feces. Metagenomic analysis revealed that oral supplementation with L. paracasei FZU103 significantly increased the relative abundance of Ruminococcus, Alistipes, Pseudoflavonifractor and Helicobacter, but decreased the levels of Blautia, Staphylococcos and Tannerella in HFD-fed mice. The relationships between lipid metabolic parameters and intestinal microbial phylotypes were also revealed by correlation heatmap and network. Furthermore, ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS)-based liver metabolomics demonstrated that L. paracasei FZU103 had a significant regulatory effect on the metabolic pathways of glycerophospholipid metabolism, fatty acid degradation, fatty acid elongation, unsaturated fatty acids biosynthesis, riboflavin metabolism, glycerolipid metabolism, primary bile acid biosynthesis, arachidonic acid metabolism, etc. Additionally, L. paracasei FZU103 intervention regulated expression of hepatic genes involved in lipid metabolism and bile acid homeostasis, and promoted fecal excretion of intestinal BAs. These findings present new evidence supporting that L. paracasei FZU103 has the potential to improve lipid metabolism, and could be used as a potential functional food for the prevention of hyperlipidemia.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hyperlipidemia; Intestinal microbiota; Lactobacillus paracasei FZU103; Lipid metabolism; UPLC-QTOF/MS-based liver metabolomics

Year:  2020        PMID: 33509508     DOI: 10.1016/j.foodres.2020.109956

Source DB:  PubMed          Journal:  Food Res Int        ISSN: 0963-9969            Impact factor:   6.475


  12 in total

1.  Intestinal Microbiomics and Metabolomics Insights into the Hepatoprotective Effects of Lactobacillus paracasei CCFM1222 Against the Acute Liver Injury in Mice.

Authors:  Weiling Guo; Shumao Cui; Xin Tang; Qiuxiang Zhang; Jianxin Zhao; Bingyong Mao; Hao Zhang
Journal:  Probiotics Antimicrob Proteins       Date:  2022-09-02       Impact factor: 5.265

2.  Indole-3-propionic Acid-aggravated CCl4-induced Liver Fibrosis via the TGF-β1/Smads Signaling Pathway.

Authors:  Fei Liu; Changfeng Sun; Yuanfang Chen; Fei Du; Yuxiang Yang; Gang Wu
Journal:  J Clin Transl Hepatol       Date:  2021-05-17

3.  The Protective Effects of Ganoderic Acids from Ganoderma lucidum Fruiting Body on Alcoholic Liver Injury and Intestinal Microflora Disturbance in Mice with Excessive Alcohol Intake.

Authors:  Ying-Jia Cao; Zi-Rui Huang; Shi-Ze You; Wei-Ling Guo; Fang Zhang; Bin Liu; Xu-Cong Lv; Zhan-Xi Lin; Peng-Hu Liu
Journal:  Foods       Date:  2022-03-25

4.  Pediococcus acidilactici FZU106 alleviates high-fat diet-induced lipid metabolism disorder in association with the modulation of intestinal microbiota in hyperlipidemic rats.

Authors:  Qing Zhang; Wei-Ling Guo; Gui-Mei Chen; Min Qian; Jin-Zhi Han; Xu-Cong Lv; Li-Jiao Chen; Ping-Fan Rao; Lian-Zhong Ai; Li Ni
Journal:  Curr Res Food Sci       Date:  2022-04-27

5.  Effect of Lactobacillus fermentum HFY06 Combined with Arabinoxylan on Reducing Lipid Accumulation in Mice Fed with High-Fat Diet.

Authors:  Fang Li; Hui Huang; Yu Zhang; Hongjiang Chen; Xianrong Zhou; Yongpeng He; Xiao Meng; Xin Zhao
Journal:  Oxid Med Cell Longev       Date:  2022-04-06       Impact factor: 6.543

6.  Matcha green tea targets the gut-liver axis to alleviate obesity and metabolic disorders induced by a high-fat diet.

Authors:  Yuefei Wang; Yueer Yu; Lejia Ding; Ping Xu; Jihong Zhou
Journal:  Front Nutr       Date:  2022-08-01

7.  Coix Seed-Based Milk Fermented With Limosilactobacillus reuteri Improves Lipid Metabolism and Gut Microbiota in Mice Fed With a High-Fat Diet.

Authors:  Zhoujie Yang; Xiaoli Zhu; Anyan Wen; Jingqi Ran; Likang Qin; Yi Zhu
Journal:  Front Nutr       Date:  2022-07-12

8.  Lactobacillus paracasei CCFM1223 Protects against Lipopolysaccharide-Induced Acute Liver Injury in Mice by Regulating the "Gut-Liver" Axis.

Authors:  Weiling Guo; Bingyong Mao; Xin Tang; Qiuxiang Zhang; Jianxin Zhao; Shumao Cui; Hao Zhang
Journal:  Microorganisms       Date:  2022-06-30

9.  Efficacy and safety of zhibitai in the treatment of hyperlipidemia: A systematic review and meta-analysis.

Authors:  Chunyang Wang; Wentai Pang; Xuechen Du; Jiani Zhai; Mengyuan Zhong; Ming Zhuang; Jiali An; Lujia Cao; Li Zhang; Wenke Zheng; Junhua Zhang
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

10.  Intestinal microbiomics and liver metabolomics insights into the preventive effects of chromium (III)-enriched yeast on hyperlipidemia and hyperglycemia induced by high-fat and high-fructose diet.

Authors:  Mei-Ting Wang; Wei-Ling Guo; Zi-Yi Yang; Feng Chen; Tian-Tian Lin; Wen-Long Li; Xu-Cong Lv; Ping-Fan Rao; Lian-Zhong Ai; Li Ni
Journal:  Curr Res Food Sci       Date:  2022-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.